Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.